ClinicalTrials.Veeva

Menu

Perceptions and Representations of Vaccination Against COVID-19 (PERCECOVAC)

C

Centre Hospitalier Intercommunal Creteil

Status

Completed

Conditions

COVID-19 Acute Respiratory Distress Syndrome

Treatments

Behavioral: Interview

Study type

Observational

Funder types

Other

Identifiers

NCT04896957
PERCECOVAC

Details and patient eligibility

About

SARS COV2, the virus that causes COVID-19, was first described in Wuhan, China. For this pathology, which causes severe respiratory infections, preventing the transmission of the virus has become fundamental, that is why vaccines have been developed. In France, this vaccination campaign took place in a context where the lack of confidence in vaccination is high:

According to a November 2020 IFOP poll, only 41% of French respondents were willing to be vaccinated against COVID-19.

To our knowledge, there are still few qualitative studies on vaccination on the current issue of vaccination against COVID-19.

Enrollment

14 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Over 18 years of age
  • Patient with a scheduled appointment in consultation or at the vaccination centre
  • Not opposed to participation in the protocol

Exclusion criteria

  • Patient under guardianship or curatorship
  • Patient unable to give free and informed consent
  • Patient under court protection
  • Patient without the cognitive capacity to ensure an interview

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems